R&D Spending Showdown: Dr. Reddy's Laboratories Limited vs Verona Pharma plc

Comparing R&D investments: Dr. Reddy's vs Verona Pharma

__timestampDr. Reddy's Laboratories LimitedVerona Pharma plc
Wednesday, January 1, 2014124020000004101058
Thursday, January 1, 20151744900000010763215
Friday, January 1, 2016178340000005579049
Sunday, January 1, 20171955100000032051299
Monday, January 1, 20181826500000024482286
Tuesday, January 1, 20191560700000043892589
Wednesday, January 1, 20201541000000044505000
Friday, January 1, 20211654100000079406000
Saturday, January 1, 20221748200000049283000
Sunday, January 1, 20231938100000017282730
Monday, January 1, 202422873000000
Loading chart...

Data in motion

R&D Spending: A Tale of Two Companies

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Dr. Reddy's Laboratories Limited, a major player in the industry, has consistently invested heavily in R&D over the past decade. From 2014 to 2023, their R&D expenses have grown by approximately 56%, peaking in 2024. In contrast, Verona Pharma plc, a smaller entity, has shown a more volatile R&D spending pattern, with a notable spike in 2021, where their expenses increased by over 90% compared to the previous year.

While Dr. Reddy's Laboratories maintains a steady upward trend, Verona Pharma's fluctuating investments highlight the challenges smaller companies face in sustaining R&D efforts. The data for 2024 is incomplete for Verona Pharma, indicating potential shifts in their strategy. This comparison underscores the diverse approaches companies take in navigating the pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025